重视质子泵抑制剂的安全性  

Focus on safety of proton pump inhibitors

作　　者：刘菲[1] 郑松柏[1] 

机构地区：[1]复旦大学附属华东医院消化科、老年医学科,上海200040

出　　处：《中国新药与临床杂志》2012年第9期493-498,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：上海市自然科学基金项目(08ZR1402000)

摘　　要：质子泵抑制剂(PPI)在临床应用已20余年,是目前临床上治疗酸相关性疾病的主要药物。临床医师普遍认为这是一类安全有效的药物,但近几年来有关其潜在不良反应的报道增多。PPI常见不良反应轻微,严重不良反应罕见,但对于高龄患者及严重肝、肾功能不全的患者应酌情减量,同时需注意与常用药物间的相互作用。当长疗程、大剂量应用时,可能产生一系列潜在的不良反应,如骨质疏松、维生素B_(12)缺乏、缺铁性贫血、肺部及肠道感染等,应引起重视。Proton pump inhibitors （PPI） has been used for more than 20 years in clinic and is the main choice for treatment of acid-related diseases. Clinicians commonly believe it is a safe and effective drug. But reports of potential adverse reactions of PPI have been increasing in recent years. The common adverse reactions of PPI are mild and serious adverse reactions are rare. However, dose of PPI should be reduced appropriately in elderly patients and patients with severe liver, renal impairment. At the same time, close attention should be paid to potential interactions of PPI with commonly used drugs. When a long course （more than 2 months） and/ or a high-close （twice the standard dose） of PPI are required, particular attention should be paid to a range of potential adverse reactions, such as osteoporosis, vitamin B12 deficiency, iron deficiency anemia, lung and intestinal infections and so on.

关 键 词：质子泵抑制剂 安全性 药物不良反应 药物相互作用 

分 类 号：R975[医药卫生—药品]